41.52
-1.27 (-2.96%)
| 前收盘价格 | 42.78 |
| 收盘价格 | 42.50 |
| 成交量 | 101,255 |
| 平均成交量 (3个月) | 367,380 |
| 市值 | 1,985,534,848 |
| 价格/销量 (P/S) | 88.36 |
| 股市价格/股市净资产 (P/B) | 4.28 |
| 52周波幅 | |
| 利润日期 | 6 Aug 2026 |
| 稀释每股收益 (EPS TTM) | -3.82 |
| 总债务/股东权益 (D/E MRQ) | 2.74% |
| 流动比率 (MRQ) | 31.01 |
| 营业现金流 (OCF TTM) | -67.45 M |
| 杠杆自由现金流 (LFCF TTM) | -47.00 M |
| 资产报酬率 (ROA TTM) | -22.89% |
| 股东权益报酬率 (ROE TTM) | -33.14% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Rapport Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.33 |
|
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 6.28% |
| 机构持股比例 | 105.23% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Trv Gp Vi, Llc | 31 Mar 2026 | 969,218 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合